Valeant Pharmaceuticals (VRX) PT Lifted to $271 at Cantor Fitzgerald

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Valeant Pharmaceuticals (VRX) PT Lifted to $271 at Cantor Fitzgerald

Valeant Pharmaceuticals (VRX) PT Lifted to $250 at Guggenheim Post Q1

April 29, 2015 10:16 AM EDT

Guggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) to $250.00 (from $210.00) following Q1 beat and better-than-expected 2016 outlook.

Chen commented, "The 1Q15 beat and better-than-expected outlook for '16+ support our positive thesis for... More

Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition

April 29, 2015 6:16 AM EDT

Valeant Pharma (NYSE: VRX) reported Q1 EPS of $2.36, versus $1.76 reported last year. Revenue for the quarter came in at $2.2 billion, versus $1.89 billion reported last year.

Valeant also announced that Howard B. Schiller has advised the Company of his decision to step down as Chief Financial Officer once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds. With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant Board and, with the Board's continued... More